Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs

Apr-15

AUTHORS : Dr Vincent Lo Re III, Center for Clinical Epidemiology and Biostatistics, 836 Blockley Hall, 423 Guardian Drive, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104-6021, USA – Email: vincentl@mail.med.upenn.edu – Profile: https://www.med.upenn.edu/apps/faculty/index.php/g275/p6951

JOURNAL : BMC Pharmacology & Toxicology

REFERENCE: 16:8

DOI : 10.1186/s40360-015-0007-z

Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs

More publications

Comparative effect of aspirin versus clopidogrel monotherapy on incident type 2 diabetes in patients with atherosclerotic cardiovascular diseases: A target trial emulation study

Postoperative Weight Loss After Antiobesity Medications and Revision Risk After Joint Replacement

Comparative effectiveness and prescribing trends of modified release versus immediate release indapamide in patients with hypertension: cohort study